Our Research

Research
Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.

 

Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.

 

Our VIEW BOOK



You can find our most recent annual report here: 2023 HMAI Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>

 

Researchers Identify Protein To Aid With Glioblastomas

Molecular Analysis Slide

In a recent study published in Nature Communications, Houston Methodist researchers, led by Kyuson Yun, PhDassociate professor of neurology, conducted a molecular analysis that identified a protein, S100A4, which could be a therapeutic target for restoring anti-tumor action of immune cells toward glioblastomas that have beguiled the immune system into protecting it.  Learn more>

Center for RNA Therapeutics Awarded Inno Fire Award

Inno Fire Awards Logo

The Center for RNA Therapeutics won the 2022 Houston Inno Fire Award from the Houston Business Journal for innovation in health care and life sciences. Learn more>

 

Latest News

Tuesday, March 26, 2024 Implantable device delivers HIV antiviral with more potency than oral drugs
A team from Houston Methodist Research Institute recently showed that a nanofluidic implant delivered an HIV drug that achieved more potency than other forms of drug administration (oral) and other HIV drugs.   The results, published in The Journal of Controlled Release, may lead to a long-acting, r...
Read more
Thursday, March 14, 2024 Researchers may have found key to deprogram cells that lead to transplant rejection
Houston Methodist researchers identified a troublesome subset of T-cells in transplant recipients that may be a more effective therapeutic target for preventing transplant rejection in patients.   Each day, 17 people die waiting for organ transplants, but getting a new organ doesn’t guarantee survi...
Read more
Thursday, January 25, 2024 Promising new ‘circRNA’ vaccines explored in CEPI-HMRI collaboration
The Coalition for Epidemic Preparedness Innovations (CEPI) is teaming up with leading scientists at the Houston Methodist Research Institute to further develop a promising type of disease-defense technology that could pave the way for new 'circular RNA’ vaccines that are more stable, durable and cos...
Read more